专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

WO2005016969A3 CD20-BINDING POLYPEPTIDE COMPOSITIONS 审中-公开
标题翻译： CD20结合多肽组合物
公开(公告)号：WO2005016969A3
公开(公告)日：2005-04-21
申请号：PCT/EP2004009033
申请日：2004-08-16
申请人： MERCK PATENT GMBH , CARR FRANCIS J , WILLIAMS STEPHEN , GILLIES STEPHEN D
发明人： CARR FRANCIS J , WILLIAMS STEPHEN , GILLIES STEPHEN D
IPC分类号： A61P37/00 , C07K16/28 , C07K16/30 , C12N15/13 , A61K39/395 , C12N15/62
CPC分类号： C07K16/2887 , A61K2039/505 , C07K16/3076 , C07K2317/24 , C07K2317/52 , C07K2317/56 , C07K2317/732 , C07K2317/734 , C07K2319/00 , Y10S424/80 , Y10S424/801
摘要： The invention relates to polypeptide compositions that bind to CD20 antigen, especially human CD20 antigen. The polypeptide composistions have the biological activity of known anti-CD20 antibodies, such as 2B8 or Leu16, but show a reduced immunogenicity as compared with the non-modified molecules. The polypeptide compositions include chimeric antibodies, antibody fragments, and fusion proteins of an antibody or antibody fragment with a cytokine.
摘要翻译：本发明涉及结合CD20抗原，特别是人CD20抗原的多肽组合物。多肽组分具有已知的抗CD20抗体如2B8或Leu16的生物学活性，但与未修饰的分子相比，表现出降低的免疫原性。多肽组合物包括嵌合抗体，抗体片段和抗体或抗体片段与细胞因子的融合蛋白。

2. 发明申请

WO02069232A2 METHOD FOR IDENTIFICATION OF T-CELL EPITOPES AND USE FOR PREPARING MOLECULES WITH REEDUCED IMMUNOGENICITY 审中-公开
标题翻译：用于鉴定T细胞外膜的方法和用于制备具有免疫原性的分子的用途
公开(公告)号：WO02069232A2
公开(公告)日：2002-09-06
申请号：PCT/EP0201688
申请日：2002-02-18
申请人： MERCK PATENT GMBH , CARR FRANCIS J , CARTER GRAHAM , JONES TIM , WILLIAMS STEPHEN , HAMILTON ANITA
发明人： CARR FRANCIS J , CARTER GRAHAM , JONES TIM , WILLIAMS STEPHEN , HAMILTON ANITA
IPC分类号： G01N33/50 , A61K9/70 , A61K38/00 , A61K38/11 , A61K47/02 , A61K47/12 , C07K14/00 , C07K14/285 , C07K14/415 , C07K14/47 , C07K14/475 , C07K14/50 , C07K14/525 , C07K14/535 , C07K14/54 , C07K14/545 , C07K14/575 , C07K14/59 , C07K14/725 , C07K16/00 , C07K16/18 , C07K16/28 , C07K16/30 , C07K16/46 , C07K19/00 , C12N9/24 , C12N9/54 , C12N9/64 , C12N15/09 , G01N33/15 , G01N33/48 , G06F19/16 , G06F19/18 , G06F19/00
CPC分类号： G06F19/16 , A61K9/7015 , A61K38/00 , A61K47/02 , A61K47/12 , C07K14/54 , C07K16/18 , C07K16/2866 , C07K16/2896 , C07K16/30 , C07K16/3046 , C07K16/464 , C07K16/465 , C07K2319/00 , G06F19/18
摘要： This invention relates to a novel approach for identification of T-cell epitopes, that give rise to an immune reaction in a living host. By means of this novel method biological compounds can be generated which have a no or at least a reduced immunogenicity when exposed to the immune system of a given species and compared with the relevant non-modified entity. Thus the invention relates also to novel biological molecules, especially proteins and antibodies, obtained by the method according to the invention.
摘要翻译：本发明涉及用于鉴定在宿主中产生免疫反应的T细胞表位的新方法。通过这种新方法，可以产生当暴露于给定物种的免疫系统且与相关未修饰实体相比较时具有或至少具有降低的免疫原性的生物化合物。因此，本发明还涉及通过根据本发明的方法获得的新型生物分子，特别是蛋白质和抗体。

3. 发明申请

WO02066514A3 ARTIFICIAL FUSION PROTEINS WITH REDUCED IMMUNOGENICITY 审中-公开
标题翻译：具有降低免疫原性的人造融合蛋白
公开(公告)号：WO02066514A3
公开(公告)日：2003-02-13
申请号：PCT/EP0201690
申请日：2002-02-18
申请人： MERCK PATENT GMBH , GILLIES STEPHEN , CARR FRANCIS J , JONES TIM , CARTER GRAHAM , HAMILTON ANITA , WILLIAMS STEPHEN , HANLON MARIAN , WATKINS JOHN , BAKER MATTHEW , WAY JEFFREY C
发明人： GILLIES STEPHEN , CARR FRANCIS J , JONES TIM , CARTER GRAHAM , HAMILTON ANITA , WILLIAMS STEPHEN , HANLON MARIAN , WATKINS JOHN , BAKER MATTHEW , WAY JEFFREY C
IPC分类号： C12N15/09 , A61K38/00 , A61K39/395 , A61P43/00 , C07K14/47 , C07K16/00 , C07K16/18 , C07K16/28 , C07K16/30 , C07K19/00 , C12P21/02 , C12N15/62
CPC分类号： C07K16/30 , C07K16/28 , C07K16/2863 , C07K2317/24 , C07K2317/34 , C07K2319/00 , C07K2319/30
摘要： The invention relates to artificial modified proteins, preferably fusion proteins, having a reduced immunogenicity compared to the parent non-modified molecule when exposed to a species in vivo. The invention relates, above all, to novel immunoglobulin fusion proteins which essentially consist of an immunoglobulin molecule or a fragment thereof covalently fused via its C-terminus to the N-terminus of a biologically active non-immunoglobulin molecule, preferably a polypeptide or protein or a biologically active fragment thereof. In a specific embodiment, the invention relates to fusion proteins consisting of an Fc portion of an antibody which is fused as mentioned to the non-immunological target molecule which elicits biological or pharmacological efficacy. The molecules of the invention have amino acid sequences which are altered in one or more amino acid residue positions but have in principal the same biological activity as compared with the non-altered molecules. The changes are made in regions of the molecules which are identified as T-cell epitopes, which contribute to an immune reaction in a living host. Thus, the invention also relates to a novel method of making such fusion proteins by identifying said epitopes comprising calculation of T-cell epitope values for MHC Class II molecule binding sites in a peptide by computer-aided methods.
摘要翻译：本发明涉及人体修饰蛋白，优选融合蛋白，当与体内物种暴露时，与亲本非修饰分子相比具有降低的免疫原性。本发明首先涉及新的免疫球蛋白融合蛋白，其基本上由免疫球蛋白分子或其通过C末端与生物活性非免疫球蛋白分子，优选多肽或蛋白质的N末端共价融合的片段组成，或其生物活性片段。在一个具体的实施方案中，本发明涉及由抗体的Fc部分组成的融合蛋白，所述Fc部分如提及的非免疫靶标分子融合而引起生物学或药理学功效。本发明的分子具有氨基酸序列，其在一个或多个氨基酸残基位置被改变，但与未改变的分子相比具有相同的生物学活性。在被鉴定为T细胞表位的分子的区域中进行改变，其有助于在宿主中的免疫反应。因此，本发明还涉及通过鉴定所述表位来制备此类融合蛋白的新方法，包括通过计算机辅助方法计算肽中MHC II类分子结合位点的T细胞表位值。

4. 发明申请

WO02062843A2 MODIFIED ERYTHROPOIETIN (EPO) WITH REDUCED IMMUNOGENICITY 审中-公开
标题翻译：具有降低免疫原性的改良型ERYTHROPOIETIN（EPO）
公开(公告)号：WO02062843A2
公开(公告)日：2002-08-15
申请号：PCT/EP0201174
申请日：2002-02-05
申请人： MERCK PATENT GMBH , CARR FRANCIS J , CARTER GRAHAM , JONES TIM , WILLIAMS STEPHEN
发明人： CARR FRANCIS J , CARTER GRAHAM , JONES TIM , WILLIAMS STEPHEN
IPC分类号： C12N15/09 , A61K9/70 , A61K38/00 , A61K38/11 , A61K38/18 , A61K38/27 , A61K47/02 , A61K47/12 , A61P7/00 , A61P7/06 , C07K7/06 , C07K7/08 , C07K14/505 , C07K14/54 , C07K16/18 , C07K16/28 , C07K16/30 , C07K16/46 , C12N15/18 , C12P21/02 , G06F17/30 , G06F19/16 , G06F19/18 , C07K14/575
CPC分类号： G06F19/16 , A61K9/7015 , A61K38/00 , A61K47/02 , A61K47/12 , C07K14/505 , C07K14/54 , C07K16/18 , C07K16/2866 , C07K16/2896 , C07K16/30 , C07K16/3046 , C07K16/464 , C07K2319/00 , G06F19/18
摘要： The present invention relates to polypeptides to be administered especially to humans and in particular for therapeutic use. The polypeptides are modified polypeptides whereby the modification results in a reduced propensity for the polypeptide to elicit an immune response upon administration to the human subject. The inention in particular relates to the modification of erythropoietin (EPO) to result in erythropoietin proteins that are substantially non-immunogenic or less immunogenic than any non-modified counterpart when used in vivo.
摘要翻译：本发明涉及特别用于人，特别是用于治疗用途的多肽。所述多肽是修饰的多肽，其中所述修饰导致多肽在施用于人受试者时引起免疫应答的倾向降低。本发明特别涉及红细胞生成素（EPO）的修饰，以产生当在体内使用时与任何未修饰的对应物基本上不具有免疫原性或较少免疫原性的促红细胞生成素蛋白。

5. 发明申请

WO02062832A3 MODIFIED HUMAN BRAIN-DERIVED NEUTROPHIC FACTOR (BDNF) WITH REDUCED IMMUNOGENICITY 审中-公开
标题翻译：具有降低免疫原性的改良人脑中性粒细胞因子（BDNF）
公开(公告)号：WO02062832A3
公开(公告)日：2003-03-13
申请号：PCT/EP0201169
申请日：2002-02-05
申请人： MERCK PATENT GMBH , CARR FRANCIS J , CARTER GRAHAM , JONES TIM , WILLIAMS STEPHEN
发明人： CARR FRANCIS J , CARTER GRAHAM , JONES TIM , WILLIAMS STEPHEN
IPC分类号： C12N15/02 , A61K9/70 , A61K38/00 , A61K38/11 , A61K38/18 , A61K38/22 , A61K47/02 , A61K47/12 , A61P25/00 , A61P25/28 , C07K7/08 , C07K14/475 , C07K14/48 , C07K14/54 , C07K16/18 , C07K16/28 , C07K16/30 , C07K16/46 , C12N15/12 , G06F19/16 , G06F19/18 , C07K7/06
CPC分类号： G06F19/16 , A61K9/7015 , A61K38/00 , A61K38/185 , A61K47/02 , A61K47/12 , C07K14/475 , C07K14/54 , C07K16/18 , C07K16/2866 , C07K16/2896 , C07K16/30 , C07K16/3046 , C07K16/464 , C07K2319/00 , G06F19/18
摘要： The present invention relates to polypeptides to be administered especially to humans and in particular for therapeutic use. The polypeptides are modified polypeptides whereby the modification results in a reduced propensity for the polypeptide to elicit an immune response upon administration to the human subject. The invention in particular relates to the modification of human brain-derived neutrophic factor (BDNF) to result in BDNF proteins that are substantially non-immunogenic or less immunogenic than any non-modified counterpart when used in vivo.
摘要翻译：本发明涉及特别用于人，特别是用于治疗用途的多肽。所述多肽是修饰的多肽，其中所述修饰导致多肽在施用于人受试者时引起免疫应答的倾向降低。本发明特别涉及人类脑源性中性粒细胞因子（BDNF）的修饰，以产生当在体内使用时与任何未修饰的对应物基本上是非免疫原性或较少的免疫原性的BDNF蛋白质。

6. 发明申请

WO2004094473A2 HUMANIZED ANTIBODIES TO INTERFERON ALPHA RECEPTOR-1 (IFNAR-1) 审中-公开
标题翻译：干扰素ALPHA受体-1（IFNAR-1）的人源化抗体
公开(公告)号：WO2004094473A2
公开(公告)日：2004-11-04
申请号：PCT/US2004012649
申请日：2004-04-23
申请人： MEDAREX INC , CARDARELLI JOSEPHINE M , CHEN TSENG-HUI TIMOTHY , KING DAVID , BEBBINGTON CHRISTOPHER R , POGUE SARAH LEE , CARR FRANCIS J , WILLIAMS STEPHEN
发明人： CARDARELLI JOSEPHINE M , CHEN TSENG-HUI TIMOTHY , KING DAVID , BEBBINGTON CHRISTOPHER R , POGUE SARAH LEE , CARR FRANCIS J , WILLIAMS STEPHEN
IPC分类号： A61K39/395 , C07K16/28 , C07K16/44 , C07K16/46 , C07K16/00
CPC分类号： C07K16/2866 , A61K2039/505 , C07K2317/24 , C07K2317/56 , C07K2317/565 , C07K2317/567 , C07K2317/70 , C07K2317/76 , C07K2317/92 , C07K2317/94
摘要： Humanized monoclonal antibodies which bind to IFNAR-1, and related antibody-based compositions and molecules, are disclosed. Also disclosed are pharmaceutical compositions comprising the humanized antibodies and therapeutic and diagnostic methods for using the humanized antibodies.
摘要翻译：公开了结合IFNAR-1的人源化单克隆抗体以及相关的基于抗体的组合物和分子。还公开了包含人源化抗体和使用人源化抗体的治疗和诊断方法的药物组合物。

7. 发明申请

WO2012106389A3 DISTRIBUTED ENERGY STORAGE SYSTEM AND METHOD OF DISTRIBUTING ENERGY 审中-公开
标题翻译：分布式能源储存系统和分配能源的方法
公开(公告)号：WO2012106389A3
公开(公告)日：2012-11-29
申请号：PCT/US2012023422
申请日：2012-02-01
申请人： S & C ELECTRIC CO , BERKOWITZ DONALD S , PORTER DAVID , BELLEI TERRENCE , SEMBER JAMES W , WILLIAMS STEPHEN
发明人： BERKOWITZ DONALD S , PORTER DAVID , BELLEI TERRENCE , SEMBER JAMES W , WILLIAMS STEPHEN
IPC分类号： H02J3/28 , H02J3/16
CPC分类号： H02J3/32 , G05B15/02 , H02J3/1807 , Y02E40/30
摘要： This patent describes embodiments of systems, apparatus and methods to provide improved control and coordination of a multiplicity of electric distribution grid-connected, energy storage units deployed over a geographically-dispersed area.
摘要翻译：该专利描述了系统，装置和方法的实施例，以提供在地理上分散的区域上部署的多个配电并网的能量存储单元的改进的控制和协调。

8. 发明申请

WO2010010382A3 METHOD OF STIFFENING A RIB DURING ASSEMBLY 审中-公开
标题翻译：在组装过程中加固RIB的方法
公开(公告)号：WO2010010382A3
公开(公告)日：2010-05-06
申请号：PCT/GB2009050889
申请日：2009-07-20
申请人： AIRBUS OPERATIONS LTD , WILLIAMS STEPHEN
发明人： WILLIAMS STEPHEN
IPC分类号： B64C3/18 , B64F5/00
CPC分类号： B64C3/187 , B64F5/10 , Y10T29/49622
摘要： A method of stiffening a rib (19, 20) during the assembly of an aircraft wing is described. A stiffener panel (40, 41) is attached to a face of the rib (19, 20). The rib is aligned with one or more wing components with the stiffener panel (40, 41) attached. An assembly operation such as drilling (16) is performed with the rib aligned and the stiffener panel attached. The stiffener panel (40, 41) is removed from the rib after the assembly operation. The stiffener panel has a resilient external sealing ring which is mounted on a face of the panel and forms an external perimeter of a vacuum cavity; and at least one resilient internal sealing ring which is mounted on the panel (20, 21) within the perimeter defined by the external sealing ring and forms an internal perimeter of the vacuum cavity. The stiffener can be attached to the rib by a vacuum clamping force, the vacuum being sealed by the external and internal sealing rings. The internal sealing ring(s) seal any holes which are present in the rib. The stiffener (40, 41) can support the rib (20, 21) during alignment to give it the required flatness.
摘要翻译：描述了在飞行器机翼的组装期间加强肋（19,20）的方法。加强板（40,41）附接到肋（19,20）的表面。肋与一个或多个机翼部件对准，并且加强板（40,41）连接在一起。执行诸如钻孔（16）的组装操作，其中肋对准并且加强板连接。在组装操作之后，加强板（40,41）从肋上移除。加强板具有弹性的外部密封环，其安装在面板的表面上并形成真空腔的外周; 以及至少一个弹性内部密封环，其安装在由外部密封环限定的周边内的面板（20,21）上并形成真空腔的内部周边。加强件可以通过真空夹紧力连接到肋上，真空由外部和内部密封环密封。内密封环密封肋中存在的任何孔。加强件（40,41）可以在对准期间支撑肋（20,21），以使其成为所需的平整度。

9. 发明申请

WO2009032071A3 ORTHOPAEDIC CEMENT MIXTURES WITH LOW WEIGHT PERCENT POLYVINYL ALCOHOL (PVA) SOLUTION 审中-公开
标题翻译：低重量聚乙烯醇（PVA）溶液的对比度水泥混合物
公开(公告)号：WO2009032071A3
公开(公告)日：2010-01-14
申请号：PCT/US2008009912
申请日：2008-08-20
申请人： SPINEMEDICA CORP , SALUMEDICA LLC , BETZ RANDAL R , BROWN REBECCAH , WILLIAMS STEPHEN
发明人： BETZ RANDAL R , BROWN REBECCAH , WILLIAMS STEPHEN
IPC分类号： A61L24/06 , A61L24/00 , A61L27/16 , A61L27/44 , A61L27/50
CPC分类号： A61K6/083 , A61K6/06 , A61L24/0063 , A61L27/425 , A61L2430/02 , C08L29/04
摘要： Orthopaedic bone cement mixtures include a primary material that has a flowable state and a solid mass state and a low weight percent amount of polyvinyl alcohol (PVA) material. The PVA material is distributed in the primary material.
摘要翻译：矫形骨水泥混合物包括具有可流动状态和固体质量状态的主要材料以及低重量百分比的聚乙烯醇（PVA）材料。 PVA材料分布在主材料中。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式